GSK Acquisition Of Corixa Means End To Royalty Payments

GSK agrees to pay $300 mil. for Corixa in an M&A play to pick up the biotech's adjuvant technology. The deal will allow GSK to avoid paying adjuvant therapy royalty payments. Corixa's technology is used in GSK's high-profile Cervarix HPV vaccine.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet